Woodline Partners’s Belite Bio BLTE Stock Holding History

Woodline Partners’s Portfolio BLTE Stock Details BLTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-18,041	Closed	-$2.89M	–	1041
2025 Q4	$2.89M	Buy	+18,041	New	+$2.14M	0.01%	725

Other funds holding BLTE

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners's BLTE Position: Q1 2026 in Review

Woodline Partners sold out of Belite Bio (BLTE) in Q1 2026, closing a stake of 18,041 shares — an estimated $2.89M sold.

Woodline Partners first reported a position in BLTE in Q4 2025 and held it in 1 quarter. The position peaked at $2.89M in Q4 2025. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

Woodline Partners reported no remaining Belite Bio position as of Q1 2026 after selling out during the quarter.
Woodline Partners sold 18,041 Belite Bio shares in Q1 2026, an estimated $2.89M.
Woodline Partners first reported a position in Belite Bio in Q4 2025 and held it in 1 quarter.
Woodline Partners's Belite Bio position peaked at $2.89M in Q4 2025.
75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.